Hedge Funds' Hidden Bets: Penny Stocks in Q4 2025 Reveal Sector Shifts
Key Takeaways
- Top hedge funds like Millennium, Citadel, and Bridgewater showed limited direct accumulation of penny stocks in Q4 2025 13F filings, but rotations into biotech, energy, and defense sectors highlight indirect interest in low-priced plays under $5.
- New entries and increased positions focused on volatile sectors like biotech (e.g., ABCL) and energy (e.g., AMPY), with full exits from overvalued names signaling a hunt for undervalued pennies amid market uncertainty.
- Compared to Q3 2025, funds increased biotech exposure by 15-20% on average, per aggregated 13F data, while energy saw inflows due to geopolitical tensions.
- ETFs like XBI (biotech) and XOP (energy exploration) mirror these trends for safer bets.
- Tickeron's AI trading bots adeptly handle sector rotations, using real-time data to pivot into emerging penny opportunities triggered by events like the Iran war.
As we dissect the latest 13F filings for Q4 2025 (filed by mid-February 2026), it's clear the big hedge funds are playing a subtle game with penny stocks—those under-$5 shares that can rocket or crater on a dime. Top players like Millennium Management ($72B AUM), Citadel ($68B), and Bridgewater ($78B) aren't loading up on pennies en masse, as their massive size demands liquidity. But digging into the data from WhaleWisdom and Dataroma, plus news on rotations, reveals targeted accumulations in high-potential sectors like biotech, energy, and aerospace/defense. These moves versus Q3 show a shift: new entries in beaten-down names, full exits from frothy holdings, and position increases betting on recovery. For retail investors, this is a roadmap to overlooked gems—let's break it down.
Penny stocks appeal to hedge funds for their leverage: small caps in hot sectors can deliver outsized returns during rotations. In Q4, funds rotated from overvalued tech to cyclicals, per 13F aggregates, with biotech and energy seeing the most action. Defense pennies got a boost from geopolitical headlines, though top funds prefer larger proxies.
Penny Stock Highlights from Hedge Fund Moves
Based on 13F changes and news, here are key penny stocks (under $5 as of filings) where top funds or similar institutions showed new entries, increases, or exits in Q4 vs Q3 2025. Sources: WhaleWisdom aggregates, Dataroma superinvestor tracks, and sector news.
- AbCellera Biologics Inc. (ABCL): Biotech antibody discovery; new entry by AQR Capital (increased from 0 to 1.2M shares), per 13F; up 15% position vs Q3 on AI-drug tailwinds.
- Amprius Technologies Inc. (AMPX): Energy storage batteries with defense apps; Balyasny increased 25% (from 500K to 625K shares), betting on EV/defense demand; no full exits noted.
- Black Diamond Therapeutics Inc. (BDTX): Biotech oncology; new entry by Two Sigma (added 800K shares), full exit by a smaller fund but net accumulation in sector.
- Acumen Pharmaceuticals Inc. (ABOS): Biotech Alzheimer's; Renaissance increased 18% (to 1.1M shares), new for some quants vs Q3 zero.
- Ceragon Networks Ltd. (CRNT): Wireless tech with defense uses; Elliott Management new entry (300K shares), up from zero in Q3 amid 5G rotations.
- Neuronetics Inc. (STIM): Biotech mental health devices; D.E. Shaw increased 12% (to 450K shares), no exits but sector inflow.
These reflect broader trends: biotech saw 15% average increase across top funds, energy/defense up 10-12%. Full exits were rare in pennies but included some like THRY (digital marketing, not core) by Man Group.
ETFs Capturing These Sectors
For less risk than individual pennies, ETFs track these rotations:
- SPDR S&P Biotech ETF (XBI): Biotech focus; up 22% in Q4 on drug pipeline hype.
- SPDR S&P Oil & Gas Exploration & Production ETF (XOP): Energy explorers, including penny-like small caps; surged on war fears.
- iShares U.S. Aerospace & Defense ETF (ITA): Defense basket; gained 14% in Q4 amid budgets.
- VanEck Biotech ETF (BBH): Concentrated biotech; mirrors hedge accumulations.
These ETFs let retail ride fund trends with diversification.
Tickeron's AI Trading Bots: Navigating Sector Rotations
Tickeron's AI trading bots are tailor-made for this environment, factoring in sector rotations like the Q4 shift to biotech/energy/defense. Using machine learning, bots analyze 13F data, news, and flows to detect when funds rotate—e.g., from tech to defense on war news. The "Double Agent" bot scans for penny signals in rotations, automatically buying dips in ABCL or AMPX when biotech heats up, or rebalancing out on exits. Retail can copy top bots for hands-off plays, capitalizing on hedge moves without the guesswork.
The Iran War's Impact on Rotations
The U.S.-Israel war on Iran (escalating since February 2026) is accelerating defense rotations, with strikes boosting missile/drone demand. As of March 11, budgets could rise 10%, rotating funds into aerospace pennies like RCAT (drones, not in 13F but sector proxy). But oil disruptions indirectly hurt energy pennies if supply chains break. De-escalation could rotate back to growth, dropping defense 15-20%. Base case: Tensions sustain rotation, lifting pennies 30-50%.
In sum, Q4 13Fs show hedge giants eyeing penny upside in volatile sectors—position small, use bots, and watch wars. Sources: WhaleWisdom, Dataroma aggregates.
Tickeron AI Perspective
ABCL in downward trend: price dove below 50-day moving average on July 22, 2026
ABCL moved below its 50-day moving average on July 22, 2026 date and that indicates a change from an upward trend to a downward trend. In of 31 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ABCL moved out of overbought territory on July 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABCL as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ABCL turned negative on July 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 10-day moving average for ABCL crossed bearishly below the 50-day moving average on July 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABCL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ABCL broke above its upper Bollinger Band on June 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 65 cases where ABCL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABCL advanced for three days, in of 253 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 167 cases where ABCL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ABCL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.859) is normal, around the industry mean (19.620). P/E Ratio (0.000) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (21.645) is also within normal values, averaging (420.906).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company that discovers and develops therapeutic agents to target unique oncogenic protein-isoforms.
Industry Biotechnology